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Abstract
Introduction: It has been reported that orexins may play an important role in GH regulation. Orexins participate in the regulation of 
pituitary hormones secretion, food intake regulation, and the sleep-wake cycle. It has been suggested that a defect of orexin A synthesis 
could be responsible for disturbances in GH synthesis in patients with acromegaly, and consequently aggravate metabolic disturbances 
caused by high levels of IGF1. 
The aim of this study: The aim of this study was to assess orexin A levels in relation to the activity of the disease and the influence on 
metabolic profile in patients with acromegaly. 
Material and methods: The subjects were 55 acromegalic patients divided into three main groups: a surgically cured acromegalic 
group (SCA); a well-controlled acromegalic group (WCA); an active acromegalic group (AA); and 29 healthy controls. In all sub-
jects, blood samples were taken to assess the concentration of orexin A, lipids, glucose, insulin and hormones of the pituitary and 
peripheral glands. 
Results: The concentration of orexin A was highest in the control group (CG) and lowest in the WCA group. The differences of orexin A 
concentration were statistically significant when each group of acromegalics were compared to the CG. There were no significant differences 
in orexin A concentration among the studied groups of patients with acromegaly. The metabolic disturbances were more often observed 
in the groups of acromegaly patients. In the AA group, orexin A concentrations correlated negatively with plasma lipids. 
Conclusions: The concentration of orexin A is reduced in acromegaly compared to healthy subjects. (Endokrynol Pol 2012; 63 (6): 463–469)
Key words: acromegaly, orexin A, metabolic disturbances
Streszczenie 
Wstęp: Sugeruje się, że oreksyny mogą odgrywać ważną rolę w regulacji wydzielania hormonu wzrostu (GH). Oreksyny biorą udział 
w regulacji wydzielania hormonów przysadki, regulacji w zakresie pobierania pokarmu i regulacji rytmu sen–czuwanie. Wydaje się, że 
zaburzenia w syntezie oreksyny A mogą być odpowiedzialne za zaburzenia w syntezie GH u pacjentów z akromegalią, a tym samym 
mogą nasilać zaburzenia metaboliczne spowodowane przez wysokie wartości IGF1. 
Cel pracy: Celem pracy była ocena zaburzeń syntezy oreksyny A u osób chorujących na akromegalię, w korelacji z aktywnością choroby 
i wpływem na profil metaboliczny u tych pacjentów. 
Materiał i metody: W badaniu wzięło udział 55 chorych na akromegalię, których podzielono na trzy podstawowe grupy: chirurgicznie 
wyleczona akromegalia (SCA), dobrze kontrolowana akromegalia (WCA), aktywna akromegalia (AA), oraz 29 osób stanowiących grupę 
kontrolną (CG). W każdej z grup oznaczono stężenie oreksyny A, stężenie lipidów, glukozy, insuliny oraz hormony przysadki i gruczołów 
obwodowych. 
Wyniki: Stężenie oreksyny A było największe w grupie CG, a najmniejsze w grupie WCA. Różnice stężeń oreksyny A były istotne 
statystycznie między wszystkimi grupami chorych na akromegalię a grupą kontrolną. Brak było znamiennych statystycznie 
różnic stężeń oreksyny A pomiędzy poszczególnymi grupami w obrębię chorych na akromegalię. Zaburzenia metaboliczne 
były częściej obserwowane w grupach pacjentów z akromegalią. W grupie AA stężenie oreksyny A korelowało ujemnie ze 
stężeniami lipidów. 
Wniosek: Stężenie oreksyny A jest obniżone u chorych na akromegalię w porównaniu z grupą kontrolną. (Endokrynol Pol 2012; 63 (6): 463–469)
Słowa kluczowe: akromegalia, oreksyna A, zaburzenia metaboliczne
Introduction
Acromegaly is a rare disease caused by GH and IGF1 
oversecretion. It is characterised by greater mortality 
compared to the general population, mainly due to 
metabolic disturbances and cardio-vascular complica-
tions [1–3]. The release of GH is regulated by many 
substances, and it has been reported that peptides such 
as orexins play an important role in the regulation of 
GH secretion [4, 5].
Orexins, recently discovered neuropeptides, are 
synthesised mainly in the posterolateral hypothalamus 
as well as peripherally. The presence of orexins receptors 
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and protein levels. It has been shown in gild glands 
that their expression is modulated during the oestrous 
cycle and by the steroid milieu [6]. The extent of the 
orexins and their receptors occurrence indicates their 
pleiotropic action, of the neurotransmitters as well as 
neuromodulators. Additionally, due to secretion into 
the peripheral blood, it has been assumed that they act 
as hormones [7, 8]. They participate in the regulation 
of pituitary hormones secretion, food intake regulation, 
and the sleep-wake cycle [9]. It has been suggested that 
a defect of orexins synthesis, mainly of orexin A, could 
be responsible for disturbances in GH synthesis and 
consequently aggravate metabolic disturbances caused 
by high IGF1 levels.
The projections of the orexins’ fibres come in the 
area of the classical nuclei, controlling GH secretion 
such as the periventricular nucleus (mainly expression 
of somatostatin) and the arcuate nucleus (the expression 
of GHRH [Growth Hormone-Releasing Hormone]) [10]. 
It has been shown that in these nuclei the orexins fibres 
coexist with the neurons showing orexins’ receptors 
expression. The impact of orexins on GH secretion is 
not clear. Studies to date have reported the suppression 
as well as the stimulation of GH secretion as a result of 
the influence of orexins [4, 5, 11].
Chen and Xu, in an experiment using porcine 
somatotropes, showed that orexin increased in vitro 
GH response to a single injection of orexin B and to 
the co-administration of orexin A and GHRH. It has 
been suggested that orexin A increases the sensitivity 
of somatotropic cells to stimulation by GHRH [4]. On 
the other hand, other studies have shown that the 
administration of orexin A caused a decrease in GH 
secretion in rats [12]. The injection of orexin A in rats has 
decreased the spontaneous secretion of GH, whereas in 
vivo no changes have been noticed in GH response to 
GHRH under the influence of orexin A [4]. It has been 
observed that the intraventricular administration of 
orexin A leads to a block of releasing of GH and GH 
response to ghrelin. It is possible that orexin A inhibits 
endogenous GHRH, and that it has no influence on GH 
responses to exogenously administered GHRH [5]. Xu 
et al. reported that orexin A augmented L-type Ca2+ 
current in somatotropes. Moreover, they suggested that 
orexin might play an important role in the regulation 
of GHRH-stimulated GH secretion via an increase in 
the L-type Ca2+ current and protein kinase C-mediated 
signalling pathways [12]. Orexin A may be involved 
in the regulatory mechanism of nutritional status and 
GH release [9].
The aim of our case-control study was the analysis 
of orexin A concentrations in patients with acromegaly 
in relation to the activity of disease and the influence on 
metabolic profile in patients with acromegaly.
Material and methods
The study was carried out in 55 patients with acrome-
galy aged 23–83 years (mean 50.85 ± 5.24), 39 women 
and 16 men, divided into three main groups according 
to the minimal GH concentration found during an oral 
glucose tolerance test (OGTT) and the IGF1 concentrati-
on. Normal, according to the age and sex concentration 
of IGF1 and the level of GH during the OGTT test below 
1 µg/L (ng/mL), was considered as a criterion of cure or 
good disease control. 18 patients with cured acromegaly 
were included in the surgically cured acromegalic (SCA) 
group. 17 patients, after failed neurosurgery, who were 
being treated with a long-acting octeotide, were inclu-
ded in the well-controlled acromegalic (WCA) group. 
20 patients who did not meet the criteria for the cure 
or good control of the disease were included in the ac-
tive acromegalic (AA) group. In this group, 15 patients 
had unsuccessful transsphenoidal surgery. Only four 
patients with acromegaly underwent radiation therapy 
(two in the AA and one in the WCA and SCA groups). 
29 healthy subjects aged 21–77 years (mean 47.86 ± 
± 15.76), 23 women and six men, were enrolled to the 
control group (CG). The CG was sex- and age-matched. 
23 patients with acromegaly required hydrocortisone 
and 22 L-thyroxin replacement. The number of subjects 
who required hormonal replacement was similar in 
each group of patients, and there was no statistically 
significant difference between groups. We did not 
observe panhypopituitarism in any patient. Thirteen 
patients with acromegaly and type 2 diabetes mellitus 
were treated with oral hypoglycaemic agents. Nineteen 
subjects among the studied received statin therapy: five 
in the AA, four in the WCA and five each in the SCA 
and CG groups, respectively. All subjects were recrui-
ted from patients of the Department of Endocrinology, 
Diabetology and Isotope Therapy, Wroclaw Medical 
University. The protocol of the study was approved 
by the local Bioethics Committee, and all subjects gave 
their informed consent.
The analyses were performed based on a division 
into groups. The first division was done on the basis 
of the activity of the disease. In the second division, 
the analysis was performed between the AA group, 
a group of patients with clinically and biochemically 
compensated acromegaly (WCA + SCA), and the CG. 
The group of patients with acromegaly (CC + SCA + 
+ WCA) and the CG were isolated in the third division. 
All patients belonging to the AA and the WCA groups 
were treated with Octreotide-LAR (long-acting release) 
at different doses, but most, irrespective of their group, 
were given the highest dose (30 mg). Five patients in 
the AA and six in the WCA groups were treated with 
Octreotide-LAR at 20 mg, and two patients in the AA 
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group at 10 mg. These patients did not tolerate higher 
doses. Body weight was highest in the AA and lowest 
in the CG groups. The difference was statistically sig-
nificant when the AA, the SCA, the WCA + SCA and 
the AA + WCA + SCA groups were compared to the 
CG group (p < 0.014; p < 0.005, p < 0.009, p < 0.004, 
respectively). Mean BMI was highest in the SCA and 
lowest in the CG groups. The difference was statist-
cally significant when the WCA, SCA, WCA + SCA and 
the AA + WCA + SCA groups were compared to the 
CG group (p < 0.003; p < 0.001, p < 0.001, p < 0.003, 
respectively). General characteristics of the subjects are 
set out in Tables I and II.
Body weight, height and blood pressure were meas-
ured in all patients who participated in the study. Pitui-
tary, thyroid and adrenal glands function was assessed 
on the basis of hormones levels. The GH, PRL, LH, FSH, 
oestradiol (E2), total testosterone (T), ACTH, and insulin 
concentrations were analysed by the chemiluminescent 
method using Immulite 2000 kits (DPC, Germany or 
USA, Siemens, USA). Normal ranges were: GH: 0.06–5 
µg/L (ng/mL), PRL: women 1.9–25 ng/mL, men: 2.5–17 
ng/mL, LH: postmenopausal women 11.3–39.8 mIU/ 
/mL, women in follicular phase 1.1–11.6 mIU/mL, men 
0.8–7.6 mIU/mL, FSH: postmenopausal women 9.7–111 
mIU/mL, women in follicular phase 2.8–11.3 mIU/mL, 
men 0.7–11.1 mUI/mL, E2: postmenopausal women 
30–140 pg/mL, women in follicular phase 0–160 pg/mL, 
T: women 0.2–0.8 ng/mL, men 1.29–7.67 ng/mL, ACTH: 
0–46 pg/mL, insulin: 6.0–27.9 µIU/mL. Serum IGF1 level 
was assessed by radioimmunologic assay using IGF-1-D-
RIT-CT kit (BioSource Europe S.A., Nivelles, Belgium), 
normal range: according to the age and sex.
Biochemical tests including lipids, insulin and 
glucose were also performed. Total Cholesterol (TCH), 
High Density Lipoprotein Cholesterol (HDL), and tri-
glycerides (TG) were studied by immunoenzymometric 
assay using Cholesterol RTU kit, HDL Cholesterol Direct 
kit and Triglicerides Enzymatique PAP 150 (BioMerieux 
s.a., France), respectively. Normal ranges: TCH 130–200 
Table I. General characteristics of groups of patients with acromegaly and the control group (basal demographics)
Tabela I. Ogólna charakterystyka grup pacjentów z akromegalią i grupy kontrolnej (podstawowe dane)
Group Age (years) Body mass [kg] Height [m] BMI [kg/m2]
AA 50.8 ± 5.2 88.1 ± 21.8* 1.7 ± 0.1#^† 29.3 ± 5.1
WCA 55.3 ± 12.4 81.4 ± 14.4 1.65 ± 0.09 29.7 ± 4.7*
SCA 54.0 ± 11.5 88.0 ± 14.5* 1.65 ± 0.1 31.7 ± 4.4*
CG 47.8 ± 15.7 74.7 ± 14.9 1.67 ± 0.0 26.8  ± 4.5
WCA + SCA 54.6 ±11.8 84.8 ± 14.6* 1.66 ± 0.09 30.7 ± 4.6*
AA + WCA +SCA 53.2 ± 13.6 86.0 ± 17.5* 1.68 ± 0.11 30.2 ± 4.8*
AA — active acromegaly group; WCA — well-controlled acromegaly group; SCA — surgically cured acromegaly group; CG — control group; *p < 0.05 
compared to CG group; #p < 0.05 compared to WCA group; ^p < 0.05 compared to SCA group; †p < 0.05 compared to WCA + SCA group
Table II. Results of hormonal and biochemical analyses in groups of patients with acromegaly and the control group
Tabela II. Wyniki badań hormonalnych i biochemicznych w grupach pacjentów z akromegalią i w grupie kontrolnej
Group GH 0 min  
[ng/mL] 
[µg/L]
GH 120 min 
[ng/mL] 
[µg/L]





TCH [mg/dL] LDL [mg/dL] HDL [mg/dL]
AA 11.5 ± 
14.93*#^†




28.5 ± 15.4* 102.6 ± 
22.8*^†
200.6 ± 44.3 127.6 ± 38.4 44.8 ±10.4*




110.7 ± 41.7# 55.8 ±15.9
SCA 1.32 ± 2.04 0.98 ± 2.79 164.9 ± 86.1 31.5 ± 11.5* 83.7 ± 10.1* 226.2 ± 37.2*144.0 ± 40.6* 54.2 ±11.2
CG 1.51 ± 2.82 0.50 ± 1.09 153.9 ± 79.6 39.2 ± 15.4 88.7 ± 10.6 197.2 ± 41.5 108.8 ± 38.9 61.3 ±22.0
WCA + SCA 1.75 ± 2.09* 1.20 ± 2.84 * 189.9 ± 110.9 29.2 ± 15.2* 89.5 ± 13.5 209.1 ± 45.1 127.3 ± 43.9 55.0 ±13.5
AA + WCA  
+ SCA
5.32 ± 10.19* 4.27 ±7.7 317.5 ± 
247.4*
28.9 ± 15.1* 94.3 ± 18.4 206.1 ± 44.7 127.4 ± 41.7 53.2 ±12.7
AA — active acromegaly group; WCA — well-controlled acromegaly group; SCA — surgically cured acromegaly group; CG — control group; *p < 0.05 
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mg/dL, HDL women 31–85 mg/dL, men 30–70 mg/dL, 
TG women 35–131.3 mg/dL, men 43.8–183.8 mg/dL. 
For each patient, the level of orexin A was measured 
in the plasma, fasting by immunoradiometric method 
using Orexin A-Magnetic Bead RIA kit (Phoenix Phar-
maceuticals, USA). The lowest level of detection was 
18.8 pg/mL. In addition, OGTT (75 g) was performed in 
acromegalic patients. During this test, the levels of GH, 
glucose and insulin were measured before and 1 and 
2 hours after the glucose ingestion. Body mass index, 
homeostasis assessment model insulin resistance index 
(HOMA-IR), and the quantitative insulin-sensitivity 
check index (QUICKI) were calculated. The study of the 
body composition was performed by the dual-energy 
X-ray absorptiometry (DXA) method using an Hologic 
DPX densitometer.
Statistical analysis was done by computer program 
Statistica for Windows, version 7.0. Parameter distribu-
tions were assessed using Shapiro-Wilk’s test. When 
a distribution was normal with equal statistical variance, 
Student’s t-test was used to assess statistically significant 
differences. Mann-Whitney’s U-test was used to assess 
statistically significant differences for other parameters. 
Pearson’s test or the Spearman’s rank correlation test 
R was used to assess the correlation between traits, 
depending on the kind of distribution. As a level, 
a statistically significant p value < 0.05 was used.
Results
The concentration of orexin A was highest in the CG and 
lowest in the WCA groups (Table II). The differences of 
orexin A levels were statistically significant when each 
group of patients with acromegaly was compared to 
the CG. There were no significant differences of orexin 
A concentration among the studied groups of patients 
with acromegaly (Fig. 1). The differences of orexin A 
were also statistically significant when we used the 
division numbers 2 and 3 and compared the group of 
patients with acromegaly  to the CG (WCA + SCA v. CG, 
AA + WCA+SCA v. CG; p < 0.005; p < 0.004, respec-
tively). A tendency to a negative correlation between 
orexin A concentration and the level of GH at 0 and 
60 minutes during the OGTT was observed. It was statis-
tically significant in the AA group (p < 0.052; p < 0.003, 
respectively). Metabolic disturbances were more often 
observed in groups of patients with acromegaly. TCH 
and LDL-cholesterol levels were highest in the SCA and 
lowest in the WCA groups. The difference was statisti-
cally significant when the SCA was compared to the 
WCA and CG groups (p < 0.007; p < 0.02, respectively). 
It was on the border of statistical significance between 
the AA and SCA groups (p < 0.092). HDL cholesterol 
was highest in the CG and lowest in the AA groups and 
it was statistically significant (p < 0.045) (Table II). TG 
levels were highest in the AA and lowest in the WCA 
groups. However, there was no statistically significant 
difference among the studied groups. The mean of body 
fat mass was highest in the WCA and lowest in the AA 
group. The differences were statistically significant 
when the following groups were compared: AA v. WCA, 
AA v. WCA+SCA, WCA+SCA v. CG (p < 0.0016; p < 
< 0.006; p < 0.0035, respectively). The mean of the 
percentage of body fat was significantly lower in the 
AA group compared to the WCA (p < 0.002). The mean 
of the lean body mass was highest in the AA group and 
lowest in the CG group. The differences were statisti-
cally significant when the following groups were com-
pared: AA v. CG, SCA v. CG, AA v. WCA, WCA + SCA v. 
CG, AA + WCA + SCA v. CG (p < 0.005; p < 0.01; p < 
0.05, p < 0.014, p < 0.003, respectively). Fasting glucose 
levels were highest in the AA group. The differences 
were statistically significant when the following groups 
were compared: AA v. CG, SCA v. CG, AA v. SCA, WCA 
v. SCA, AA v. WCA + SCA (p < 0.03; p < 0.05; p < 0.002; 
p < 0.012; p < 0.025, respectively). Prolactin levels were 
higher in all groups of  patients with acromegaly than 
in controls. There were no such differences between 
groups of subjects in other hormones (FSH, LH, ACTH, 
T, E2) studied (not shown).
Figure 1. Concentration of orexin A in relation to the activity 
of acromegaly. AA — active acromegaly group; WCA — well-
controlled acromegaly group; SCA — surgically cured acromegaly 
group; CG — control group; (AA v. CG, WCA v. CG, SCA v. CG, 
p < 0.008; p < 0.005; p < 0.039, respectively) 
Rycina 1. Stężenia oreksyny A w zależności od aktywności 
akromegalii: AA — grupa z aktywną akromegalią, WCA — grupa 
z dobrze kontrolowaną akromegalią, SCA — grupa z chirurgicznie 
wyleczoną akromegalią, CG — grupa kontrolna  (AA v. CG, WCA 
v. CG, SCA v. CG, p < 0.008; p < 0.005; p < 0.039, odpowiednio)
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In the AA group, orexin A concentrations corre-
lated negatively with lipids: TCH and LDL (Fig. 2 
and 3). In the other groups, a tendency to a nega-
tive correlation between the above parameters was 
observed but they were not statistically significant. 
Orexin A positively correlated with the mean of body 
fat mass and the percentage of the body fat in the AA 
and the WCA groups (r = 0.569, p < 0.01; r = 0.583, 
p < 0.02, respectively). In the WCA group, orexin A 
correlated negatively with the dose of Octreotide
-LAR (r = –0.601, p < 0.01). In each group of patients 
with acromegaly, a tendency to negative correlations 
between orexin A and glucose, insulin and HOMA 
index were observed.
Discussion
The influence of the somatotropic axis on the secretion 
of orexin A is not clear. We could not find any previous 
reports on orexin A metabolism in acromegaly. The cur-
rent study is the first aimed at the assessment of orexin 
A concentrations in patients with acromegaly in relation 
to the activity of disease and the metabolic profiles in 
patients with acromegaly.
Most of the performed experimental studies have indi-
cated the influence of orexins, especially of orexin A, on the 
secretion of GH. Since the discovery that orexin neurons 
occur in the arcuate nucleus, where there are huge num-
bers of GHRH neurons, it is supposed that orexin inhibits 
the endogenous GHRH tension. Consequently, it leads to 
a decrease in GH and IGF1 secretion. This might explain 
the inhibitory effect of orexin A on the basal secretion 
of GH and the lack of influence on GH response to the 
administration of exogenous GHRH [4, 5].
We have observed that orexin A concentration 
was highest in controls and lowest in the WCA group. 
The difference in the concentration of orexin A was 
statistically significant when each group of patients 
with acromegaly was compared to the CG. This was 
independent of the kind of division carried out. There 
were no significant differences of orexin A concentration 
among the studied groups of patients with acromegaly. 
This may indicate the disorders of orexin A metabo-
lism in patients suffering from acromegaly. Moreover, 
reduced levels of orexin A in both the WCA and SCA 
groups suggest that abnormal orexin A secretion is 
sustainable. The confirmation of an inhibitory influ-
ence of orexin A on GH secretion may be the negative 
correlation between GH and orexin A concentrations. 
This was statistically significant in the AA group. In the 
other groups, we observed a trend toward a negative 
relationship between these parameters. The lowest con-
centration of orexin A was observed in the WCA group, 
which may be associated with the additional effects of 
somatostatin analogues on the metabolism of orexin 
A. In our study, we showed a statistically significant 
negative correlation between orexin A and the dose of 
octreotide. This observation requires further study. We 
do not know how somatostatin analogues may affect 
the orexin-GHRH pathway.
In each group of patients with acromegaly, we ob-
served a tendency to a negative correlation between 
the concentration of orexin A and the concentrations 
of glucose and insulin at 120 min of the OGTT and the 
HOMA index. It is known that insulin has an antago-
nistic effect in relation to orexin A and the correlation 
between these parameters is negative, as observed in 
previous studies [14]. In acromegaly, deficiency of orexin 
Figure 2. Correlation between orexin A and total cholesterol in 
the active acromegaly (AA) group
Rycina 2. Zależność między stężeniami oreksyny A i całkowitego 
cholesterolu w grupie z aktywną akromegalią (AA)
Figure 3. Correlation between orexin A and LDL in the active 
acromegaly (AA) group
Rycina 3. Zależność między stężeniami oreksyny A i LDL 
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A may be the consequence of GH hypersecretion as 
well as the excessive secretion of insulin. Hypotheti-
cally, these results may suggest that the deficiency of 
orexin A may influence the disorder of carbohydrate 
metabolism in acromegaly.
Lipids disorders are very common in acromegaly. 
The influence of GH on lipids metabolism is associated 
with increased lipolysis. In addition, it causes the redis-
tribution of body fat, increasing the amount of visceral 
fat [15]. Moreover, the abnormalities of lipids are aggra-
vated by insulin resistance, which changes the activity 
of lipoprotein lipase [16]. This leads to an increase of 
triglycerides levels, a decrease in HDL synthesis, and 
a rearrangement of the quality of LDL cholesterol. This 
causes a change in lipids profile for the atherogenic one.
The highest triglycerides concentration was ob-
served in the AA and the lowest in the WCA groups, in 
which we also noticed the smallest HOMA index. The 
WCA group was characterised by the lowest level of 
TCH and LDL cholesterol, and the difference compared 
to the SCA group was statistically significant. This con-
firmed the dependence of lipids disturbances on insulin 
resistance [17–19] and their amelioration while being 
treated with somatostatin analogues. The changes in 
the lipid profile observed in the WCA group are con-
sistent with observations made by others [20, 21]. The 
highest concentrations of TCH and LDL cholesterol were 
observed in the SCA group. Our results are similar to other 
reports which have suggested that effective treatment 
of acromegaly is not always connected to a reversion to 
a normal lipids profile [22]. HDL cholesterol concentration 
was highest in the CG and lowest in the AA groups. The 
WCA group was characterised by a higher level of HDL, 
compared to the AA and SCA groups, which is related to 
the influence of somatostatin analogues. Analysis of the 
modification in lipids profile based on division number 
3 (AA + SCA + WCA) v. the CG, revealed that groups of 
patients with acromegaly had higher levels of TCH, LDL 
cholesterol and triglycerides and a lower level of HDL 
cholesterol. In the cases of LDL and HDL cholesterol, the 
differences were on the border of statistical significance. 
The changes in lipid profile in patients with acromegaly 
are consistent with previous observations indicating that 
levels of triglycerides and TCH remain unchanged or 
increase [23–25], whereas HDL cholesterol remains un-
changed or decreases [24, 26].
The alterations in lipids were correlated with the 
concentration of orexin A. The modifications in lipids 
profile were the greatest in the AA group. We noticed 
a statistically significant correlation between orexin A 
and TCH and LDL cholesterol. This may suggest the 
dependence of lipids metabolism on orexin A. It is 
known that orexin A participates in the regulation of 
food intake and energy expenditure [9].
The changes in lipids profile in acromegaly are 
similar to those observed in patients with narcolepsy 
with known orexins deficiency [27, 28]. A lot of the 
metabolic disturbances were observed in patients with 
narcolepsy. These changes are independent of BMI or 
the food intake and they are the result of orexins defi-
ciency. It has been shown that significant metabolic dis-
turbances occurred, despite the lack of increase in BMI 
and hypophagia. These disturbances were the increase 
in the level of TCH and triglycerides and the decrease 
in HDL cholesterol, accompanied by significant insulin 
resistance and increased glucose level. This suggests the 
direct effect of orexin on numerous metabolic processes 
[29, 30]. Although the mechanism of disturbances of 
metabolism of orexins in patients with acromegaly is 
different than in patients with narcolepsy, the influ-
ence on lipids metabolism appears to be similar. For 
this reason, we suppose that the deficiency of orexin A 
may increase the metabolic disturbances occurring in 
the course of acromegaly in the same way as in patients 
with narcolepsy.
Acromegaly is also associated with a decrease in fat 
mass and an increase in lean body mass. This is a result 
of the lipolytic effect of GH [31, 32]. The highest lean 
body mass was observed in the AA and the smallest 
in the CG groups, and the difference was statistically 
significant. The AA group was also characterised by 
the smallest value of fat mass and body fat percentage. 
The highest values of these parameters were observed 
in the WCA group. This indicates that good control 
of acromegaly, by using somatostatin analogues, may 
eliminate the effect of GH. Matsumar et al. showed 
a positive correlation of orexin A with BMI and fat body 
mass in healthy subjects [33]. The level of orexin A de-
creases in patients with obesity and its correlation with 
BMI is negative [31]. In our study, body weight and BMI 
in the groups of patients with acromegaly were higher 
than in the CG group, regardless of the division. We did 
not observe pathologic obesity among the patients, so 
the correlation of orexin A with BMI should be correct. 
So, in theory, higher BMI in patients with acromegaly 
groups should correlate with higher levels of orexin A 
in these groups.
The data presented in this paper requires more 
analysis, including factors that may impact upon the 
relationship between the levels of orexin A and GH in 
acromegaly. The limitations of the presented research 
are the varying duration of the disease in patients, as 
well as the duration of the therapy with somatostatin 
analogues, which could affect the results. The relation-
ships between orexin A and the concentrations of GH, 
IGF1 should be assessed before and after treatment 
(surgical as well as pharmacological) to eliminate their 
influence on the results.
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The concentration of orexin A is reduced in patients suf-
fering from acromegaly compared to healthy subjects. 
We suppose that orexin A deficiency may increase the 
metabolic abnormalities in patients with acromegaly, 
especially regarding the impact on the metabolism of 
lipids. This hypothesis requires further study.
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